Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2024 clinical trials
Featured trial
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).

  • 0 views
  • 16 Sep, 2022
  • 12 locations
Featured trial
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC

cancer
cancer of the ovary
bladder tumor
measurable disease
  • 36 views
  • 11 Jul, 2022
  • 19 locations
Featured trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

  • 0 views
  • 19 Jun, 2022
  • 16 locations
Featured trial
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been

solid tumor
solid tumors
  • 84 views
  • 10 May, 2022
  • 53 locations
Featured trial
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

monotherapy at the RDE(s) in participants with selected advanced or metastatic solid tumors. Part 1A (dose escalation) will determine the recommended dose of INCB123667 for expansion (RDE) and the maximum

  • 2 views
  • 14 Sep, 2022
  • 3 locations
Featured trial
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

preliminary efficacy of INCA00186 when given alone or in combination with INCB106385 and/or retifanlimab in participants with specific advanced solid tumors; squamous cell carcinoma of the head and neck

  • 8 views
  • 19 Sep, 2022
  • 9 locations
Featured trial
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Carcinoma

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

cancer
solid tumors
  • 55 views
  • 10 May, 2022
  • 9 locations
Featured trial
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.  

cancer
solid tumor
solid tumors
measurable disease
metastatic cancer
  • 38 views
  • 10 May, 2022
  • 13 locations
Featured trial
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

INCMGA00012 administered IV every two or four weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors.  The study consists of two phases, a Dose

cancer
endometrial carcinoma
primary cancer
measurable disease
  • 295 views
  • 10 May, 2022
  • 17 locations
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor

solid tumor
FGFR3
FGFR1
malignancies
cancer
  • 112 views
  • 10 May, 2022
  • 50 locations